Physicochemical and functional characterization of vaccine antigens and adjuvants

Expert Review of Vaccines

Volumn 13, Issue 5, 2014, Pages 671-685

  Dey, Antu K ^a   Malyala, Padma ^b   Singh, Manmohan ^a  

^a Novartis Vaccines Inc   (United States)

^b Novartis Vaccines Inc   (United States)

Author keywords

analytical assays; antigen'adjuvant interactions; vaccine; vaccine adjuvant; vaccine antigen; vaccine characterization

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; ANTIGEN; GLYCOPROTEIN; IMMUNOLOGICAL ADJUVANT; RECOMBINANT PROTEIN; VACCINE; HLA ANTIGEN CLASS 2;

DRUG FORMULATION; DRUG PURITY; DRUG QUALITY; DRUG SAFETY; EMULSION; IMMUNE RESPONSE; MOLECULAR SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; TECHNOLOGY; ANIMAL; CHEMISTRY; HUMAN; IMMUNOLOGY; PHYSIOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; PHYSICOCHEMICAL PHENOMENA; VACCINES;

EID: 84902794211     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.907528     Document Type: Review

References (137)

1. Rappuoli R, Aderem A. 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011;473(7348):463-9
2. Rappuoli R. Bridging the knowledge gaps in vaccine design. Nat Biotechnol 2007;25(12): 1361-6
3. Ulmer JB, Valley U, Rappuoli R. Vaccine manufacturing: Challenges and solutions. Nat Biotechnol 2006;24(11):1377-83
4. Coffey CS, Kairalla JA. Adaptive clinical trials: Progress and challenges. Drugs R D 2008;9(4):229-42
5. Corey L, Nabel GJ, Dieffenbach C, et al. HIV-1 vaccines and adaptive trial designs. Sci Transl Med 2011;3(79):79ps13
6. Lang T. Adaptive trial design: Could we use this approach to improve clinical trials in the field of global health? Am J Trop Med Hyg 2011;85(6):967-70
7. Swanson KA, Settembre EC, Shaw CA, et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA 2011;108(23):9619-24
8. Dormitzer PR, Grandi G, Rappuoli R. Structural vaccinology starts to deliver. Nat Rev Microbiol 2012;10(12):807-13
9. Kassa A, Dey AK, Sarkar P, et al. Stabilizing Exposure of Conserved Epitopes by Structure Guided Insertion of Disulfide Bond in HIV-1 Envelope Glycoprotein. PLoS One 2013;8(10):e76139
10. Steel J, Lowen AC, Wang TT, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010;1:1
11. Noble JE and Bailey MJ. Quantitation of protein. Methods Enzymol 2009;463:73-95
12. Dey AK, Zhang Y, Ng K. Manuscript in preparation. 2013
13. Rhodes DG, Laue TM. Determination of protein purity. Methods Enzymol 2009;463: 677-89
14. Guideline on validation of the limulus amebocyte lysate test as an end-product endotoxin test for human and animal parenteral drugs, biological products, and medical devices 1987 United States Pharmacopeia (USP), 2011, Chapter , Bacterial Endotoxins Test 2011
15. Kelleher NL. Top-down proteomics. Anal Chem 2004;76(11):197A-203A
16. Siuti N and NL. Kelleher. Decoding protein modifications using top-down mass spectrometry. Nat Methods 2007;4(10): 817-21
17. Capriotti AL, Cavaliere C, Foglia P, et al. Intact protein separation by chromatographic and/or electrophoretic techniques for top-down proteomics. J Chromatogr A 2011;1218(49):8760-76
18. Creskey MC, Li C, Wang J, et al. Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE. Vaccine 2012;30(32):4762-70
19. Williams TL, Pirkle JL, Barr JR. Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometry. Vaccine 2012;30(14):2475-82
20. Williams TL, Luna L, Guo Z, et al. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008;26(20):2510-20
21. Downard KM. Contributions of mass spectrometry to structural immunology. J Mass Spectrom 2000;35(4):493-503
22. Rhodes DG, Bossio RE, Laue TM. Determination of size, molecular weight, and presence of subunits. Methods Enzymol 2009;463:691-723
23. Liu J, Andya JD, Shire SJ. A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation. Aaps J 2006;8(3): E580-9
24. Baldwin MA, Medzihradszky KF, Lock CM , et al. Matrix-Assisted laser desorption/ionization coupled with quadrupole/orthogonal acceleration time-of-flight mass spectrometry for protein discovery, identification, and structural analysis. Anal Chem 2001;73(8):1707-20
25. Kendrick BS, Kerwin BA, Chang BS, Philo JS. Online size-exclusion highperformance liquid chromatography light scattering and differential refractometry methods to determine degree of polymer conjugation to proteins and protein-protein or protein-ligand association states. Anal Biochem 2001;299(2):136-46
26. Wen J, Arakawa T, Philo JS. Size-exclusion chromatography with on-line light-scattering, absorbance, and refractive index detectors for studying proteins and their interactions. Anal Biochem 1996; 240(2):155-66
27. Ye H. Simultaneous determination of protein aggregation, degradation, and absolute molecular weight by size exclusion chromatography-multiangle laser light scattering. Anal Biochem 2006;356(1): 76-85
28. Philo JS. A critical review of methods for size characterization of non-particulate protein aggregates. Curr Pharm Biotechnol 2009;10(4):359-72
29. Gabrielson JP, Brader ML, Pekar AH, et al. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci 2007;96(2): 268-79
30. Philo JS. Is any measurement method optimal for all aggregate sizes and types? Aaps J 2006;8(3):E564-71
31. Carpenter JF, Randolph TW, Jiskoot W, et al. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 2009;98(4):1201-5
32. Demeule B, Messick S, Shire SJ, Liu J. Characterization of particles in protein solutions: Reaching the limits of current technologies. Aaps J 2010;12(4):708-15
33. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 2012; 11(7):527-40
34. Barnard JG, Babcock K, Carpenter JF. Characterization and quantitation of aggregates and particles in interferon-beta products: Potential links between product quality attributes and immunogenicity. J Pharm Sci 2013;102(3):915-28
35. Bee JS, Goletz TJ, Ragheb JA. The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: A shared perspective. J Pharm Sci 2012; 101(10):3580-5
36. Filipe V, Hawe A, Carpenter JF, Jiskoot W. Analytical approaches to assess the degradation of therapeutic proteins. TrAC Trends in Analytical Chemistry 2013;49: 118-25
37. Arakawa T, Prestrelski SJ, Kenney WC, Carpenter JF. Factors affecting short-Term and long-Term stabilities of proteins. Adv Drug Deliv Rev 2001;46(1-3):307-26
38. Carpenter JF, Chang BS, Garzon-Rodriguez W, Randolph TW. Rational design of stable lyophilized protein formulations: Theory and practice. Pharm Biotechnol 2002;13:109-33
39. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: Some practical advice. Pharm Res 1997;14(8): 969-75
40. Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm Res 2003;20(9):1325-36
41. Arakawa T, Kita Y, Carpenter JF. Protein-solvent interactions in pharmaceutical formulations. Pharm Res 1991;8(3):285-91
42. Carpenter JF, Arakawa T, Crowe JH. Interactions of stabilizing additives with proteins during freeze-Thawing and freeze-drying. Dev Biol Stand 1992;74: 225-38; discussion 238-9
43. Pace N. Conformational stability of globular proteins. Trends Biochem Sci 1970;15: 14-17
44. Carpenter JF, Crowe LM, Crowe JH. Stabilization of phosphofructokinase with sugars during freeze-drying: Characterization of enhanced protection in the presence of divalent cations. Biochim Biophys Acta 1987;923(1):109-15
45. Carpenter JF, Crowe JH. The mechanism of cryoprotection of proteins by solutes. Cryobiology 1988;25(3):244-55
46. Tang X, Pikal MJ. Design of freeze-drying processes for pharmaceuticals: Practical advice. Pharm Res 2004;21(2):191-200
47. Carpenter JF, Martin B, Loomis SH, Crowe JH. Long-Term preservation of dried phosphofructokinase by sugars and sugar/zinc mixtures. Cryobiology 1988;25(4): 372-6
48. Back JF, Oakenfull D, Smith MB. Increased thermal stability of proteins in the presence of sugars and polyols. Biochemistry 1979; 18(23):5191-6
49. Gekko K, Koga S. Increased thermal stability of collagen in the presence of sugars and polyols. J Biochem 1983;94(1):199-205
50. Carpenter JF, Crowe JH. An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry 1989;28(9):3916-22
51. Roy S, Henderson I, Nayar R, et al. Effect of pH on stability of recombinant botulinum serotype A vaccine in aqueous solution and during storage of freeze-dried formulations. J Pharm Sci 2008;97(12): 5132-46
52. Chang BS, Hershenson S. Practical approaches to protein formulation development. In: Carpenter JF, Manning MC, editors. Rational design of stable protein formulation. Kluwer Academic, NY,USA; 2002,.
53. Kasper JC, Winter G, Friess W. Recent advances and further challenges in lyophilization. Eur J Pharm Biopharm 2013;85(2):162-9
54. Carpenter JF, Manning MC, Randolph TW. Long-Term storage of proteins. Curr Protoc Protein Sci 2002;Chapter 4:Unit 4 6
55. Abdul-Fattah AM, Truong-Le V, Yee L, et al. Drying-induced variations in physicochemical properties of amorphous pharmaceuticals and their impact on Stability II: Stability of a vaccine. Pharm Res 2007;24(4):715-27
56. Abdul-Fattah AM, Truong-Le V, Yee L, et al. Drying-induced variations in physicochemical properties of amorphous pharmaceuticals and their impact on stability (I): Stability of a monoclonal antibody. J Pharm Sci 2007;96(8): 1983-2008
57. Patel SM, Pikal MJ. Lyophilization process design space. J Pharm Sci 2013;102(11): 3883-7
58. Friess W, Winter G. Meeting the challenges in freeze-drying of pharmaceuticals and biologicals. Eur J Pharm Biopharm 2013; 85(2):161
59. Joshi SB, Bhambhani A, Zeng Y, Middaugh CR. An empirical phase diagram/high throughput screening approach to the characterization and formulation of biopharmaceuticals. Formulation and process development strategies for manufacturing biopharmaceuticals. Jameel F, Hershenson S, editor. John Wiley & Sons; Hoboken, NJ, USA: 2010. p. 173-204
60. Maddux NR, Rosen IT, Hu L, et al. An improved methodology for multidimensional high-Throughput preformulation characterization of protein conformational stability. J Pharm Sci 2012; 101(6):2017-24
61. Hu L, Joshi SB, Liyanage MR, et al. Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal vaccine. J Pharm Sci 2013;102(2):387-400
62. Peek LJ, Brandau DT, Jones LS, et al. A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine. Vaccine 2006;24(31-32):5839-51
63. Arighi CN, Rossi JP, Delfino JM. Temperature-induced conformational transition of intestinal fatty acid binding protein enhancing ligand binding: A functional, spectroscopic, and molecular modeling study. Biochemistry 1998;37(47): 16802-14
64. Celej MS, Montich GG, Fidelio GD. Protein stability induced by ligand binding correlates with changes in protein flexibility. Protein Sci 2003;12(7):1496-506
65. Matulis D, Lovrien R. 1-Anilino-8-naphthalene sulfonate anion-protein binding depends primarily on ion pair formation. Biophys J 1998;74(1):422-9
66. Iyer V, Maddux N, Hu L, et al. Comparative signature diagrams to evaluate biophysical data for differences in protein structure across various formulations. J Pharm Sci 2013;102(1):43-51
67. Kamerzell TJ, Esfandiary R, Joshi SB, et al. Protein-excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev 2011;63(13):1118-59
68. Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: Concepts, achievements and perspectives. Expert Rev Vaccines 2007;6(5): 723-39
69. Rappuoli R, Mandl CW, Black S, De Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol 2011; 11(12):865-72
70. Zepp F. Principles of vaccine design-Lessons from nature. Vaccine 2010;28(Suppl 3): C14-24
71. Glenny AT, Pope CG, Waddington H, Wallace U. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926;29:31-40
72. Shirodkar S, Hutchinson RL, Perry DL, et al. Aluminum compounds used as adjuvants in vaccines. Pharm Res 1990; 7(12):1282-8
73. Clapp T, Siebert P, Chen D, Jones Braun L. Vaccines with aluminum-containing adjuvants: Optimizing vaccine efficacy and thermal stability. J Pharm Sci 2011;100(2): 388-401
74. Seeber SJ, White JL, Hem SL. Predicting the adsorption of proteins by aluminium-containing adjuvants. Vaccine 1991;9(3):201-3
75. Morefield GL, HogenEsch H, Robinson JP, Hem SL. Distribution of adsorbed antigen in mono-valent and combination vaccines. Vaccine 2004;22(15-16):1973-84
76. Hem SL, White JL. Characterization of aluminum hydroxide for use as an adjuvant in parenteral vaccines. J Parenter Sci Technol 1984;38(1):2-10
77. White JL, Hem SL. Characterization of aluminium-containing adjuvants. Dev Biol (Basel) 2000;103:217-28
78. Hem SL, Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007;6(5):685-98
79. Hem SL, White JL. Structure and properties of aluminum-containing adjuvants. In: Powell ME, Newman MJ, editors, Vaccine design; 1995. p. 249-276.
80. Vessely C, Estey T, Randolph TW, et al. Effects of solution conditions and surface chemistry on the adsorption of three recombinant botulinum neurotoxin antigens to aluminum salt adjuvants. J Pharm Sci 2007;96(9):2375-89
81. Hafner AM, Corthesy B, Merkle HP. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Adv Drug Deliv Rev 2013;65(10):1386-99
82. O'Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines 2003;2(2):269-83
83. Singh M, Chakrapani A, O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007;6(5):797-808
84. Morel S, Didierlaurent A, Bourguignon P, et al. Adjuvant system AS03 containing alpha-Tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011;29(13):2461-73
85. Calabro S, Tritto E, Pezzotti A, et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 2013; 31(33):3363-9
86. O'Hagan DT, Ott GS, Nest GV, et al. The history of MF59((R)) adjuvant: A phoenix that arose from the ashes. Expert Rev Vaccines 2013;12(1):13-30
87. Tsai TF. Fluad(R)-MF59(R)-Adjuvanted influenza vaccine in older adults. Infect Chemother 2013;45(2):159-74
88. Podda A, Del Giudice G. MF59-Adjuvanted vaccines: Increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003;2(2):197-203
89. Aucouturier J, Dupuis L, Deville S, et al. Montanide ISA 720 and 51: A new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002;1(1):111-18
90. Allison AC. Squalene and squalane emulsions as adjuvants. Methods 1999; 19(1):87-93
91. Muderhwa JM, Matyas GR, Spitler LE, Alving CR. Oil-in-water liposomal emulsions: Characterization and potential use in vaccine delivery. J Pharm Sci 1999; 88(12):1332-9
92. Cotte JF, Sonnery S, Martial F, et al. Characterization of surfactants in an oil-in-water emulsion-based vaccine adjuvant using MS and HPLC-MS: Structural analysis and quantification. Int J Pharm 2012;436(1-2):233-9
93. Lidgate DM, Fu RC, Byars NE, et al. Formulation of vaccine adjuvant muramyldipeptides. 3. Processing optimization, characterization, and bioactivity of an emulsion vehicle. Pharm Res 1989;6(9):748-52
94. Fox CB, Anderson RC, Dutill TS, et al. Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids Surf B Biointerfaces 2008;65(1):98-105
95. Kazzaz J, Singh M, Ugozzoli M, et al. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J Control Release 2006;110(3):566-73
96. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005; 11(4 Suppl):S63-8
97. Xu F, Valiante NM, Ulmer JB. Small molecule immunopotentiators as vaccine adjuvants. In: Singh M, editor. Vaccine adjuvants and delivery systems. John Wiley & Sons, Inc., Hoboken, NJ, USA: 2006
98. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine 2011;29(17):3341-55
99. Vessely C, Estey T, Randolph TW, et al. Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution. J Pharm Sci 2009;98(9):2970-93
100. Hansen B, Malyala P, Singh M, et al. Effect of the strength of adsorption of HIV 1 SF162dV2gp140 to aluminum-containing adjuvants on the immune response. J Pharm Sci 2011;100(8):3245-50
101. Vessely C, Estey T, Randolph TW, et al. Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution. J Pharm Sci 2009;98(9):2970-93
102. Zhu D, Huang S, McClellan H, et al. Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer. Vaccine 2012;30(2):189-94
103. Zhu D, Saul A, Huang S, et al. Use of o-phthalaldehyde assay to determine protein contents of Alhydrogel-based vaccines. Vaccine 2009;27(43):6054-9
104. Zhu D, Huang S, Gebregeorgis E, et al. Development of a Direct Alhydrogel Formulation Immunoassay (DAFIA). J Immunol Methods 2009;344(1):73-8
105. Colclough N, Ruston L, Tam K. Aqueous solubility in drug discovery chemistry, DMPK, and biological assays. In: Mannhold R, Kubinyi H, Folkers G, editors. Methods and principles in medicinal chemistry: Drug bioavailability John Wiley & Sons, Inc., Hoboken, NJ, USA: 2009
106. Amari JV, Levesque P, Lian Z, et al. Concentration determination of a recombinant vaccine antigen adsorbed onto an alum adjuvant by chemiluminescent nitrogen detection. Pharm Res 2005;22(1): 33-7
107. Ugozzoli M, Laera D, Nuti S, et al. Flow cytometry: An alternative method for direct quantification of antigens adsorbed to aluminum hydroxide adjuvant. Anal Biochem 2011;418(2):224-30
108. Vallhov H, Kupferschmidt N, Gabrielsson S, et al. Adjuvant properties of mesoporous silica particles tune the development of effector T cells. Small 2012;8(13):2116-24
109. Romero Mendez IZ, Shi Y, HogenEsch H, Hem SL. Potentiation of the immune response to non-Adsorbed antigens by aluminum-containing adjuvants. Vaccine 2007;25(5):825-33
110. Lai X, Zheng Y, Jacobsen S, et al. Determination of adsorbed protein concentration in aluminum hydroxide suspensions by near-infrared transmittance spectroscopy. Appl Spectrosc 2008;62(7): 784-90
111. Anderson RC, Fox CB, Dutill TS, et al. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces 2010;75(1):123-32
112. Misquith A, Fung HW, Dowling QM, et al. In vitro evaluation of TLR4 agonist activity: Formulation effects. Colloids Surf B Biointerfaces 2014;113:312-19
113. Dowling QM, Sivananthan SJ, Guderian JA, et al. Modulating potency: Physicochemical characteristics are a determining factor of TLR4-Agonist nanosuspension activity. J Pharm Sci 2014. [Epub ahead of print]
114. Hansen B, Belfast M, Soung G, et al. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine 2009;27(6):888-92
115. Egan PM, Belfast MT, Gimenez JA, et al. Relationship between tightness of binding and immunogenicity in an aluminum-containing adjuvant-Adsorbed hepatitis B vaccine. Vaccine 2009;27(24): 3175-80
116. Schofield TL. Vaccine stability study design and analysis to support product licensure. Biologicals 2009;37(6):387-96; discussion 421-3
117. Krause PR. Goals of stability evaluation throughout the vaccine life cycle. Biologicals 2009;37(6):369-78; discussion 421-3
118. Dobbelaer R, Pfleiderer M, Haase M, et al. Guidelines on stability evaluation of vaccines. Biologicals 2009;37(6):424-34; discussion 421-3
119. Schofield T, Krause PR. Stability evaluation of vaccines. Biologicals 2009;37(6):355
120. Egan W, Schofield T. Basic principles of stability. Biologicals 2009;37(6):379-86; discussion 421-3
121. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366(14):1275-86
122. Liao HX, Bonsignori M, Alam SM, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013; 38(1):176-86
123. Kamerzell TJ, Middaugh CR. The complex inter-relationships between protein flexibility and stability. J Pharm Sci 2008;97(9): 3494-517
124. Teilum K, Olsen JG, Kragelund BB. Protein stability, flexibility and function. Biochim Biophys Acta 2011;1814(8):969-76
125. Chaudhuri R, Cheng Y, Middaugh CR, Volkin DB. High-Throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability. Aaps J 2014;16(1):48-64
126. Friesner RA, Abel R, Goldfeld DA, et al. Computational methods for high resolution prediction and refinement of protein structures. Curr Opin Struct Biol 2013; 23(2):177-84
127. Comellas G, Rienstra CM. Protein structure determination by magic-Angle spinning solid-state NMR, and insights into the formation, structure, and stability of amyloid fibrils. Annu Rev Biophys 2013;42: 515-36
128. Lucic V, Rigort A, Baumeister W. Cryo-electron tomography: The challenge of doing structural biology in situ. J Cell Biol 2013;202(3):407-19
129. Carpenter JF, Randolph TW, Jiskoot W, et al. Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: Essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci 2010;99(5):2200-8
130. Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 2009;98(9):2909-34
131. Zhou L, Yang L, Tilton S, Wang J. Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery. J Pharm Sci 2007;96(11): 3052-71
132. Zolls S, Gregoritza M, Tantipolphan R, et al. How subvisible particles become invisible-relevance of the refractive index for protein particle analysis. J Pharm Sci 2013; 102(5):1434-46
133. Hawe A, Schaubhut F, Geidobler R, et al. Pharmaceutical feasibility of sub-visible particle analysis in parenterals with reduced volume light obscuration methods. Eur J Pharm Biopharm 2013;85(3 Pt B):1084-7
134. Narhi LO, Jiang Y, Cao S, et al. A critical review of analytical methods for subvisible and visible particles. Curr Pharm Biotechnol 2009;10(4):373-81
135. Scherer TM, Leung S, Owyang L, Shire SJ. Issues and challenges of subvisible and submicron particulate analysis in protein solutions. Aaps J 2012;14(2):236-43
136. Jiskoot W, Randolph TW, Volkin DB, et al. Protein instability and immunogenicity: Roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci 2012;101(3):946-54
137. Werk T, Volkin DB, Mahler HC. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods. Eur J Pharm Sci 2014;53:95-108